Bitcoin Deposit Promotes Holmes to Board
Bitcoin Depot (NASDAQ: BTM) shares climbed Tuesday. The U.S.-based Bitcoin ATM operator and leading fintech company today announced the appointment of Alex Holmes to its Board of Directors and Audit Committee. Holmes is a globally recognized leader in payments, compliance, and blockchain innovation, with more than 25 years of experience guiding financial services companies through transformation, regulatory complexity, and global expansion. As a member of Bitcoin Depot’s Board and Audit Committee, Holmes will provide strategic guidance as the crypto industry continues to rapidly evolve.“Alex has a proven track record of scaling financial services companies while maintaining the highest standards of compliance and consumer trust. His expertise will be critical in helping to guide Bitcoin Depot's next phase of growth,” said CEO Brandon Mintz. “As we continue to expand our footprint, set new industry standards of compliance, and expand crypto access for customers across North America and beyond, we couldn’t be more thrilled to welcome Alex on board.”Holmes currently serves as Executive Vice Chairman of United Texas Bank, a strategic advisor to several Web3 ventures including Orobit Inc., and a board member of Jingle Pay / Acamas Group in Dubai. He previously spent nearly two decades at MoneyGram International, where he served as Chairman and CEO from 2016-2025. BTM shares captured five cents, or 1.3%, to $3.83.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


